Literature DB >> 18596390

Venous access ports: frequency and management of complications in oncology patients.

Karin Jordan1, Timo Behlendorf, Alexey Surov, Thomas Kegel, Gita Maher, Hans-Heinrich Wolf.   

Abstract

Totally implantable venous access ports have been in use now for over 20 years. They are valuable instruments for long-term intravenous treatment of patients with cancer. Apart from perioperative difficulties, the typical complications associated with venous access ports are venous thrombosis, port infection, extravasation, pinch off syndrome, dislocation, occlusion and catheter leakages. The vast majority of these complications are avoidable, or at least the complication rate can be reduced with health care personnel training and education of patients. This review will give a broad overview on the frequency and possible complications related to port devices. Furthermore, this review suggests strategies for management including proposals to avoid such complications. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596390     DOI: 10.1159/000140451

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  10 in total

Review 1.  [Antineoplastic drug-induced extravasation].

Authors:  Maike de Wit
Journal:  Med Klin (Munich)       Date:  2010-11

2.  Is there any effect of first-day usage of a totally implantable venous access device on complications?

Authors:  Hasan Karanlik; Hatice Odabas; Ilknur Yildirim; Ilker Ozgur; Berkay Kilic; Fatma Sen; Sidika Kurul; Adnan Aydiner
Journal:  Int J Clin Oncol       Date:  2015-04-25       Impact factor: 3.402

3.  Totally Implantable Central Venous Port Catheters: Radiation Exposure as a Function of Puncture Site and Operator Experience.

Authors:  Martin Jonczyk; Bernhard Gebauer; Roman Rotzinger; Dirk Schnapauff; Bernd Hamm; Federico Collettini
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

4.  Central venous port systems as an integral part of chemotherapy.

Authors:  Ulf K Teichgräber; Robert Pfitzmann; Herbert A F Hofmann
Journal:  Dtsch Arztebl Int       Date:  2011-03-04       Impact factor: 5.594

5.  Central Venous Catheter Insertion in Colorectal Cancer Patients, PICC or PC?

Authors:  Lijuan Yin; Jinhua Li
Journal:  Cancer Manag Res       Date:  2020-07-14       Impact factor: 3.989

6.  Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.

Authors:  Yoichiro Yoshida; Seiichiro Hoshino; Naoya Aisu; Masayasu Naito; Syu Tanimura; Ai Mogi; Toshihiro Tanaka; Keiji Hirata; Kazuo Tamura; Yuichi Yamashita
Journal:  Int J Clin Oncol       Date:  2014-05-10       Impact factor: 3.402

7.  Outcome Comparison of Totally Implantable Venous Access Device Insertions Between Surgeons and Radiologists in Australia.

Authors:  Darius Dastouri; William T McSweeney; Matthew Leaning; Rasika Hendahewa
Journal:  Cureus       Date:  2022-03-17

8.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

9.  A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.

Authors:  Yoichiro Yoshida; Keiji Hirata; Hiroshi Matsuoka; Shigeyoshi Iwamoto; Masahito Kotaka; Hideto Fujita; Naoya Aisu; Seiichiro Hoshino; Takeo Kosaka; Kotaro Maeda; Fumiaki Kiyomi; Yuichi Yamashita
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162

10.  Totally implantable venous access devices: retrospective analysis of different insertion techniques and predictors of complications in 796 devices implanted in a single institution.

Authors:  Elisa Granziera; Marco Scarpa; Angelo Ciccarese; Bogdan Filip; Matteo Cagol; Valentina Manfredi; Rita Alfieri; Connie Celentano; Sandra Cappellato; Carlo Castoro; Muzio Meroni
Journal:  BMC Surg       Date:  2014-05-08       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.